ALK is an inclusion eligibility criterion in 9 clinical trials for ALK-positive large B-cell lymphoma, of which 9 are open and 0 are closed. Of the trials that contain ALK status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].

BCL2 is an inclusion eligibility criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL2 status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].

BCL6 is an inclusion eligibility criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].

IRF4 is an inclusion eligibility criterion in 1 clinical trial for ALK-positive large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IRF4 status and ALK-positive large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain MYC status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [3].